Spectrum Pharmaceuticals Inc (SPPI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
Jan 31, 2023: Spectrum Pharmaceuticals provides update on ROLVEDON (eflapegrastim-xnst) injection and announces unaudited fourth quarter 2022 financial results
Jan 04, 2023: Spectrum Pharmaceuticals Announces Management Changes
Nov 25, 2022: Spectrum Pharmaceuticals reaffirms focus on the commercialization of ROLVEDON (eflapegrastim-xnst) injection
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Spectrum Pharmaceuticals Inc (Spectrum) is a biopharma company that acquires, develops, and commercializes novel drug candidates for treatment of cancer. The company’s pipeline products include ROLONTIS, for treatment of chemotherapy-induced neutropenia helps to reduce the frequency of multiplication of tumors. Poziotinib, an irreversible tyrosine kinase inhibitor, for non-small cell lung cancer (NSCLC) tumors with various mutations. This product is in phase 2 trials and lead candidate for the organization. The company has R&D facilities in, Massachusetts and California, the US. The company operates in the US, Europe, Japan, and other countries. Spectrum is headquartered in Henderson, Nevada, the US.Spectrum Pharmaceuticals Inc Key Recent Developments
Mar 18, 2023: Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate UpdateJan 31, 2023: Spectrum Pharmaceuticals provides update on ROLVEDON (eflapegrastim-xnst) injection and announces unaudited fourth quarter 2022 financial results
Jan 04, 2023: Spectrum Pharmaceuticals Announces Management Changes
Nov 25, 2022: Spectrum Pharmaceuticals reaffirms focus on the commercialization of ROLVEDON (eflapegrastim-xnst) injection
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- UroGen Pharma Ltd
- Pfizer Inc
- AstraZeneca Plc
- Rain Oncology Inc
- Cullinan Oncology Inc
- Aeterna Zentaris Inc
- Novartis Pharmaceuticals Corp
- Eli Lilly and Co
- Celgene Corp
- Bayer Corp
- Aeterna Zentaris Inc
- Cullinan Oncology Inc
- Attralus Inc
- Novartis Pharmaceuticals Corp
- Biogen Inc
- UroGen Pharma Ltd
- GSK plc
- Endo International Plc
- Bristol-Myers Squibb Co
- Sanofi S.A.
- Rain Therapeutics Inc
- Pfizer Inc
- AstraZeneca Plc
- Genomic Health Inc